Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1272-1280

  Du, Lutao ^a   Xiao, Xiaoyan ^a   Wang, Chuanxin ^a   Zhang, Xuhua ^b   Zheng, Ni ^a   Wang, Lili ^a   Zhang, Xin ^a   Li, Wei ^a   Wang, Shun ^a   Dong, Zhaogang ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HUMAN LEUKOCYTE ANTIGEN G; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR ESCAPE;

ADULT; AGED; CELL LINE, TUMOR; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 79959217991     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01951.x     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Starzynska T. Molecular epidemiology of gastric cancer. Dig Dis 2007; 25: 222-4.
3. Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M, Yamauchi H. Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol 2003; 4: 423-8.
4. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
5. Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996; 274: 792-5.
6. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001; 22: 553-5.
7. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol 2008; 29: 125-32.
8. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 2007; 17: 469-79.
9. Ishigami S, Natsugoe S, Miyazono F et al. HLA-G expression in gastric cancer. Anticancer Res 2006; 26: 2467-72.
10. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007; 14: 2721-9.
11. Cai MY, Xu YF, Qiu SJ et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 2009; 15: 4686-93.
12. Parmiani G. Tumor-infiltrating T cells - friend or foe of neoplastic cells? N Engl J Med 2005; 353: 2640-1.
13. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-48.
14. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
15. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
16. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.
17. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 465-72.
18. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81: 199-252.
19. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248: 220-3.
20. Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res 2008; 68: 627-30.
21. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105: 1694-8.
22. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 2007; 128: 1002-9.
23. Paul P, Rouas-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510-5.
24. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 2004; 16: 644-50.
25. Clements CS, Kjer-Nielsen L, Kostenko L et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 2005; 102: 3360-5.
26. Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007; 17: 413-21.
27. Nizar S, Copier J, Meyer B et al. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009; 100: 1697-703.
28. Lin A, Zhu CC, Chen HX et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med 2010; 14: 2318-29.
29. Lin A, Chen HX, Zhu CC et al. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 2010; 14: 2162-71.
30. Zhu CB, Wang CX, Zhang X, Zhang J, Li W. Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer 2011; 128: 617-22.
31. Komohara Y, Harada M, Ishihara Y et al. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep 2007; 18: 1463-8.